The severe coronavirus disease 2019 (COVID-19) is associated with coagulopathy.
Anticoagulants, such as low-molecular-weight heparin, warfarin, thrombin inhibitors, and …

Introduction Despite the use of unfractionated heparin (UFH) or low molecular weight
heparin (LMWH), rates of thromboembolic disease, and subsequent morbidity and mortality …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-
19, is currently developing into a rapidly disseminating and an overwhelming worldwide …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a novel envelope virus
that causes coronavirus disease 2019 (COVID‐19). Hallmarks of COVID‐19 are a puzzling …

COVID-19 is widely epidemic in the world and poses a great threat to our life. Coagulopathy
is one of the major characteristics in the COVID-19 patients. A growing number of studies …

Purpose: Heparin-based regimens are recommended for anticoagulation in hospitalized
patients with COVID-19 though a study reported similar mortality with apixaban in critically ill …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus
disease 2019 (COVID-19), which can induce multisystem disease. Human angiotensin …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) commonly complicates
with coagulopathy. A syndrome called Long-COVID-19 is emerging recently in COVID-19 …

December 2019 will never be forgotten in the history of medicine when an outbreak of
pneumonia of unknown etiology in Wuhan, China sooner or later prompted the World Health …

Anticoagulant drugs have been used to prevent and treat thrombosis. However, they are
associated with risk of hemorrhage. Therefore, prior to their clinical use, it is important to …